Individualized Medicine Biobank for Mitochondrial Diseases

Overview

About this study

The Mitochondrial Disease Biobank is a place to store blood and tissue samples from people with symptoms of mitochondrial disease. Health information about each donor will be attached to the samples.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age birth-100 years, male or female, any race/ethnicity
  • Potential participant shall have a confirmed diagnosis of a mitochondrial disease or a suspected diagnosis based on a review of clinical history by a Mitochondrial Disease Biobank working group member using the clinical criteria listed in the table below
  • Selected participants shall have at least two documented conditions contained within the minor clinical criteria
    • Minor Criteria
      • Symptoms compatible with a mitochondrial defect
      • Smaller numbers of RRF or widespread electron microscopy abnormalities of mitochondria
      • Antibody-based demonstration of an mito defect or residual activity of an mito complex 20%–30% in a tissue, 30%–40% in a cell line, or 30%–40% in >2 tissues
      • Fibroblast ATP synthesis rates 2–3 SD below mean, or fibroblasts unable to grow in galactose media
      • Nuclear or mtDNA mutation of probable pathogenicity
      • One or more metabolic indicators of impaired metabolic function
  • OR one condition in the major criteria with evidence of a condition in the minor criteria, will be considered for inclusion of a participant of appropriate age
    • Major Criteria
      • Multi-systemic symptoms characteristic of mito disorder
      • Progressive clinical course with episodes of exacerbation
      • A family history strongly indicative of an mtDNA mutation
      • Exclusion of other metabolic or non-metabolic disorders
      • >2% ragged red fibers (RRF) in skeletal muscle
      • Cytochrome c oxidase negative fibers (>2-5%) or residual activity of a mito complex <20% in a tissue; <30% in a cell line, or <30% in >2 tissues
      • Fibroblast ATP synthesis rates >3 SD below mean
      • Nuclear or mtDNA mutation of undisputed pathogenicity
  • 1st-degree relatives of affected participants (described above) are also invited to participate in the project.
  • In addition, samples from participants with one of the following mitochondrial disease diagnosis will be included:
    • Alpers’ progressive sclerosing poliodystrophy 
    • Barth syndrome 
    • CPEO 
    • Dominant optic atrophy
    • Friedriech’s Ataxia
    • Hereditary paraganglioma 
    • Hereditary spastic paraplegia 
    • Kearns-Sayre syndrome Leber hereditary optic neuroretinopathy
    • Leigh and Leigh-like Syndrome 
    • MELAS 
    • MERRF
    • NARP 
    • Pearson syndrome 
    • Wolfram syndrome 
    • Mitochondrial fatty acid oxidation disorder 
    • Urea cycle defect

Exclusion Criteria:

  • Unwilling to provide informed consent
  • Unwilling to consent to providing biospecimens to be stored in the biobank for an indefinite amount of time and to be used in future research studies of as yet unknown design
  • Does not have a diagnosis of mitochondrial disease or clinical symptoms that are indicative of a potential mitochondrial disease as determined by a chart review by at least one Individualized Medine Biobank for Mitochondrial Disease working-group member

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Devin Oglesbee, Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions